07-SEP-2025 6:10

GU ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum 1 Y 0 Induction SST 1273 952 109 66 31 4 0 09/24/2018 329 137
            952 109 66 31 4 0      
 
    2 Y 1 Standard Systemic Therapy Only   342 44 22 8 2 1 09/24/2018    
        2 SST + Surgery/RT   338 37 18 11 3 0      
            680 81 40 19 5 1      
 
  S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only 1 Y 0 Pre-Rand. SST 332 202 45 24 12 4 0 03/08/2021 263 97
            202 45 24 12 4 0      
 
    2 Y 1 Systemic Immuno. Only   67 13 9 3 1 0 03/08/2021    
        2 Nephrectomy + Systemic Immuno.   67 20 9 3 2 0      
            134 33 18 6 3 0      
 
  S1937-Blad, Mets, Eribulin + Gem vs SOC 1 Y 1 Physician Choice Chemo 184 48 29 12 7 3 0 06/28/2021 245 75
        2 Eribulin   8 0 0 0 0 0      
        3 Eribulin + Gemcitabine   47 26 11 7 3 2      
            103 55 23 14 6 2      
 
  S2200-pRCC, Adv, Cabo ± Atezo 1 Y 1 Cabozantinib Only 200 17 3 2 0 0 0 03/24/2023 186 75
        2 Cabozantinib + Atezolizumab   17 5 2 2 0 0      
            34 8 4 2 0 0      
 
  S2210-Pros, High Risk, BRCA, Neoadj Carbo 1 Y 1 Carboplatin + Surgery 44 5 2 2 0 0 0 03/01/2024 143 40
            5 2 2 0 0 0      
 
  S2312-Pros, MCRPC, Cab +/- Carb 1 Y 0 Signed informed consent 500 44 44 27 16 6 0 11/27/2024 251 83
            44 44 27 16 6 0      
 
    2 Y 1 Cabazitaxel + Prednisone   12 12 6 2 0 0 11/27/2024    
        2 Cabazitaxel + Carboplatin + Prednisone   13 13 7 2 1 0      
            25 25 13 4 1 0      
 
Yes A031702-GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) 1 E Total Registrations   27 1 0 0 0 0 08/09/2019 243 88
            27 1 0 0 0 0      
 
  A032103-Urothelial, All Stg, MRD-Based Adj Tx 0 E Total Registrations   39 37 23 12 3 0 03/19/2024 359 141
            39 37 23 12 3 0      
 
    1 E Total Registrations   23 21 15 4 1 1 03/19/2024    
            23 21 15 4 1 1      
 
    2 E Total Registrations   2 2 2 0 0 0 03/19/2024    
            2 2 2 0 0 0      
 
  NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide 1 E Total Registrations   15 1 1 1 0 0 09/25/2020 275 93
            15 1 1 1 0 0      
 
  NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx 1 E Total Registrations   18 7 4 1 0 0 03/29/2023 253 86
            18 7 4 1 0 0      
 
  NRGGU012-Renal, Stg IV, Stereo Abl Rad Therapy 1 E Total Registrations   8 4 2 1 1 0 01/10/2024 261 86
            8 4 2 1 1 0      
 
No A031701-Bladder, ddGC for MIBC with DDR Tumor Alt 1 E Total Registrations   26 3 3 2 0 0 12/17/2018 177 55
            26 3 3 2 0 0      
 
    2 E Total Registrations   20 2 0 0 0 0 12/17/2018    
            20 2 0 0 0 0      
 
    3 E Total Registrations   3 1 0 0 0 0 12/17/2018    
            3 1 0 0 0 0      
 
  A031801-GU, mRCC, Cabozantinib ± Radium-223 1 E Total Registrations   15 0 0 0 0 0 11/06/2020 111 39
            15 0 0 0 0 0      
 
  EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT 1 E Total Registrations   20 7 6 2 0 0 04/25/2019 46 17
            20 7 6 2 0 0      
 
    2 E Total Registrations   2 2 2 1 1 0 04/25/2019    
            2 2 2 1 1 0      
 
  EA8191-Pros, Local vs Systemic Thrpy 0 E Total Registrations   66 19 1 1 1 1 09/24/2021 193 62
            66 19 1 1 1 1      
 
    1 E Total Registrations   66 19 1 1 1 1 09/24/2021    
            66 19 1 1 1 1      
 
  EA8192-Blad, High Grade UTUC, Durv + Chemo 1 E Total Registrations   4 0 0 0 0 0 02/23/2022 146 49
            4 0 0 0 0 0      
 
  NRGGU010-Pros, Parallel De-Intens & Intens Trials 1 E Total Registrations   70 24 3 3 0 0 01/03/2022 454 165
            70 24 3 3 0 0      
 
    2 E Total Registrations   64 22 2 2 0 0 01/03/2022    
            64 22 2 2 0 0      
 
  NRGGU013-Prostate, High-Risk, Five Fraction Radiation 1 E Total Registrations   10 6 5 2 0 0 05/28/2024 273 99
            10 6 5 2 0 0      
 

07-SEP-2025 6:10

GU Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2427 Blad, MIBC, RT + Pembrolizumab 1 Registration 04-Sep-25